Tiffany A. Traina, MD
Data from the phase III EMBRACA trial showed the superiority in progression-free survival (PFS) with the PARP inhibitor talazoparib in patients with germline BRCA1/2
-mutant metastatic HER2-negative breast cancer, including patients with triple-negative disease (TNBC).
on Breast Cancer, Tiffany A. Traina, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discussed the potential for PARP inhibitors, as well as immunotherapy and antibody-drug conjugates, for the treatment of patients with TNBC.
OncLive: What advances have we seen in TNBC?
: There are 3 advances in TNBC I highlighted from the 2017 San Antonio Breast Cancer Symposium. The first are the data on the PARP inhibitor talazoparib in patients with metastatic disease and germline BRCA1/2
mutations. The second is the interest in immuno-oncology agents and checkpoint inhibitors. The third are the developments in antibody-drug conjugates and the encouraging results of sacituzumab govitecan (IMMU-132). This is the antibody-drug conjugate against Trop-2 that is conjugated to a metabolite of irinotecan.
What is the prevalence of BRCA mutations in TNBC? How have PARP inhibitors affected this population of patients?
The prevalence of germline BRCA
mutations is difficult to fully understand because physicians are unclear what the ultimate denominator is. The data presented at the 2017 San Antonio Breast Cancer Symposium showed that there are patients who should undergo clinical genetic testing so they can be aware of their germline BRCA
... to read the full story